Today: 18 May 2026
Commonwealth Bank of Australia share price slips as GDP data lifts RBA rate-hike nerves
4 March 2026
1 min read

Commonwealth Bank of Australia share price slips as GDP data lifts RBA rate-hike nerves

SYDNEY, March 4, 2026, 16:57 AEDT — After-hours trading.

  • CBA slid 1.6% at the close, caught in a wider retreat across Australian financial stocks.
  • Traders scrambled to adjust near-term rate bets as stronger growth combined with worries over oil supply.
  • Attention turns to the RBA’s policy meeting coming up in mid-March, with inflation numbers due out in late April also on the radar.

Shares of Commonwealth Bank of Australia slipped 1.6% to close at A$171.13 on Wednesday. The stock moved in a range from A$170.91 up to A$173.48 during the session.

This is a real signal: big banks are back to being a fast gauge for interest-rate risk. A swing in rate outlook doesn’t just hit funding costs—it can jolt loan appetite and reshape how the market sizes up credit risk, occasionally in one sweep.

Sentiment stayed sour. Financial stocks shed 1.8%, staring down a fifth loss in a row. Westpac, ANZ, and National Australia Bank were each hit hard—those shares slipped anywhere from 1.3% to as much as 2.7% during the session, according to a Reuters wrap.

Australia posted 0.8% GDP growth for the December quarter, bringing the annual rate to 2.6%—the quickest clip seen in nearly three years, according to Wednesday’s data. “Today’s data will keep the RBA on high alert and increase the likelihood of a rate hike in May,” said Stephen Smith, partner at Deloitte Access Economics. Reuters

Reserve Bank of Australia Governor Michele Bullock upped the ante the day before, telling a Sydney business summit, “I’m not making a prediction about March but it will be a live meeting.” She cautioned traders not to bet on the central bank waiting until the next inflation readout before moving. Three-year bond yields picked up further after Bullock’s comments. CBA’s Ashwin Clarke said his team leans toward a move in May, “but recent data flow lifts the risk of March.” Reuters

For investors holding Commonwealth Bank, higher policy rates have a double edge. They tend to lift interest income, yet sharper tightening may put pressure on borrowers and curb mortgage credit growth.

Oil prices spike on Middle East supply worries, and that’s been enough to trigger selling in banks and other rate-sensitive shares whenever inflation jitters pop up. Some of this comes down to a straightforward risk-on, risk-off trade.

That could shift, though. Should energy prices steady and consumers remain wary with their wallets, the RBA might stay put, giving bond yields room to pull back—a move that could help bank stocks breathe. The risk? A steeper rate climb, squeezing households harder and lifting the odds of loan losses.

Traders won’t have to wait long for fresh signals. The RBA’s Monetary Policy Board is set to meet March 16–17, and markets are eyeing the next CPI print on April 29.

Latest articles

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

18 May 2026
Quince Therapeutics was last quoted at $1.15 before Monday’s Nasdaq open after Nantahala Capital Management disclosed 7.52% beneficial ownership. The company’s latest filing reported no current product candidates and raised substantial doubt about its ability to continue as a going concern. Quince is seeking shareholder approval for another reverse stock split at its June 11 meeting. The company remains out of compliance with Nasdaq’s $50 million market value rule.
Macy’s Gains Pre-Market as Berkshire Buys In — What’s Ahead for Traders

Macy’s Gains Pre-Market as Berkshire Buys In — What’s Ahead for Traders

18 May 2026
Macy’s shares rose in premarket trading after Berkshire Hathaway disclosed a new stake of 3.04 million shares, valued at about $55 million as of March 31. The stock closed Friday at $18.41 and last traded at $18.99 premarket with 128,170 shares exchanged. Macy’s will report first-quarter results on June 3. Tariffs, fuel costs, and weak discretionary spending remain risks for the retailer.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

18 May 2026
ImmunityBio said Monday five U.S. patents protect its Anktiva-plus-BCG bladder cancer treatment through at least 2035, following an exclusive U.S. supply deal with Japan BCG Laboratory. The company plans to seek FDA approval for the Tokyo-172 BCG strain, which is not yet approved in the U.S. ImmunityBio shares last traded at $7.97 before the Nasdaq open.
Why Virax Biolabs Stock Is Jumping Before the Bell Today

Why Virax Biolabs Stock Is Jumping Before the Bell Today

18 May 2026
Virax Biolabs shares jumped in pre-market trading Monday, indicated at $0.3458 after closing Friday at $0.1535. The move followed a sponsored TV segment featuring CEO James Foster and a new SEC filing showing Armistice Capital holds 4.99% of shares. ViraxImmune, the company’s main test, remains in development and is not approved for diagnostic use. No new company press release appeared over the weekend.

Popular

Sunshine Biopharma Up Premarket After Steep Fall; Traders Track $6M Filing

Sunshine Biopharma Up Premarket After Steep Fall; Traders Track $6M Filing

18 May 2026
Sunshine Biopharma shares jumped about 147% to $0.70 in premarket trading Monday after a steep drop Friday, following news of a $6 million share-and-warrant registration and a quarterly net loss of $1.24 million. The company reported first-quarter sales fell 9.1% to $8.1 million, citing the end of distribution deals in 2025.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 04.03.2026

Snowflake edges closer to the sales floor as EY and Canva roll out “agentic” AI platform
Next Story

Snowflake edges closer to the sales floor as EY and Canva roll out “agentic” AI platform

Go toTop